37 results on '"Portoghese, Philip S."'
Search Results
2. Effect of opioid receptor ligands on the μ-S196A knock-in and μ knockout mouse vas deferens
- Author
-
Portoghese, Philip S., Law, Ping-Yee, and Loh, Horace H.
- Subjects
- *
OPIOID receptors , *LIGANDS (Biochemistry) , *VAS deferens , *CHEMICAL inhibitors - Abstract
We have determined the effect of naltrexone, naloxone, [d-Ala2,d-Leu5]enkephalin (DADLE), and morphine on the μ-S196A opioid receptor knock-in and μ-opioid receptor knockout mouse vas deferens preparations. The antagonists, naltrexone and naloxone, exhibited agonist activity and possessed IC50 values that were 14- and 37-fold greater than morphine on the S196A preparation. Morphine was found to be threefold more potent at S196A relative to wild-type μ-opioid receptor. The mouse vas deferens data suggest that S196 in transmembrane helix 4 of the μ-opioid receptor modulates efficacy. It is proposed that this may be due to decreased dimerization of the receptor. Identical IC50 values of DADLE obtained on the wild-type, S196A knock-in, and μ-opioid receptor knockout preparations support the absence of μ–δ heterodimers in the mouse vas deferens. [Copyright &y& Elsevier]
- Published
- 2003
- Full Text
- View/download PDF
3. Boron tribromide-catalyzed rearrangement of 7,7...
- Author
-
Gao, Peng and Portoghese, Philip S.
- Subjects
- *
KETONES , *ORGANIC chemistry , *SCIENTIFIC experimentation , *REACTIVITY (Chemistry) - Abstract
Presents information on a possible mechanistic pathway for a novel boron tribromide-catalyzed rearrangement, of ketones to allylic alcohols which was discovered in the 7-phenylmorphinan-6-one system. Reaction involvement; What ketones are liable to under acidic conditions; Reactions of diphenylhydrocodone under boron tribromide treatment at room temperature.
- Published
- 1996
- Full Text
- View/download PDF
4. Opiate dienes as dienophiles in the Diels--Alder reactions with 1-cyano-o-quinodimethane.
- Author
-
Kshirsagar, Tushar A. and Portoghese, Philip S.
- Subjects
- *
ORGANIC chemistry , *DIELS-Alder reaction , *NARCOTICS - Abstract
Presents information regarding the Diels--alder reactions of opiates. What the naturally occurring opiates contains; How is the Diels--alder reaction enhanced; Chemical description of the opiates.
- Published
- 1998
- Full Text
- View/download PDF
5. Monophenylation of morphinan-6-ones with diphenyliodonium iodide.
- Author
-
Gao, Peng and Portoghese, Philip S.
- Subjects
- *
KETONES , *ARYLATION , *REACTIVITY (Chemistry) - Abstract
Illustrates that hydrocodone can be converted to 7-phenylhydrocodone by reacting its lithium enolate with diphenyliodonium iodide. Use of the Chen and Koser method to phenylate hydrocodone; 7alpha stereochemistry of the phenylation product; Epimerization of the monophenylation product; Additional evidence in support of the epimerization pathway; Stereochemical assignment.
- Published
- 1995
- Full Text
- View/download PDF
6. Identity of the putative δ1-opioid receptor as a δ–κ heteromer in the mouse spinal cord
- Author
-
Portoghese, Philip S. and Lunzer, Mary M.
- Subjects
- *
OPIOID receptors , *DRUG receptors - Abstract
In view of the co-localization of spinal δ- and κ-opioid receptors, we have investigated the interaction of selective opioid receptor agonists and antagonists in the spinal cord of mice in order to determine if these receptors are organized as heteromers. The finding that norbinaltorphimine (κ) antagonized [d-Pen2,5]enkephalin (δ1), but not deltorphin II (δ2), strongly suggests that the putative δ1-subtype is a δ–κ heteromer. Studies with selective opioid receptor (ant)agonists support this conclusion. [Copyright &y& Elsevier]
- Published
- 2003
- Full Text
- View/download PDF
7. MMG22 Potently Blocks Hyperalgesia in Cisplatin-treated Mice.
- Author
-
Cataldo, Giuseppe, Lunzer, Mary M., Akgün, Eyup, Wong, Henry L., Portoghese, Philip S., and Simone, Donald A.
- Subjects
- *
HYPERALGESIA , *NEURALGIA , *MICE , *NERVOUS system injuries , *EXPERIMENTAL arthritis , *PAIN management , *VISCERAL pain - Abstract
• The bivalent ligand MMG22 consists of a MOR agonist and mGluR5 antagonist. • MMG22 reduced mechanical hyperalgesia produced by cisplatin in mice. • MMG22 reduced hyperalgesia without tolerance. • MMG22 may produce antinociception through the formation of a MOR-mGluR5 heteromer. MMG22 is a bivalent ligand containing MOR agonist and mGluR5 antagonist pharmacophores connected by a 22-atom linker. Intrathecal (i.t.) administration of MMG22 to inflamed mice has been reported to produce fmol-range antinociception in the reversal of LPS-induced hyperalgesia. MMG22 reduced hyperalgesia in the spared nerve injury (SNI) model of neuropathic pain at 10 days after injury but not at 30 days after injury, perhaps related to the inflammation that occurs early after injury but subsequently subsides. The present study determined the efficacy of MMG22 in cisplatin-treated male mice in order to provide data relating to the efficacy of MMG22 in the treatment of neuropathic pain that is associated with inflammation. Groups of eight mice each received daily intraperitoneal (i.p.) injections of cisplatin for seven days to produce robust mechanical allodynia defined by the decrease in withdrawal threshold using an electronic von Frey applied to the plantar surface of the hind paw. Intrathecal administration of MMG22 potently reduced mechanical hyperalgesia (ED 50 0.04 fmol/mouse) without tolerance, whereas MMG10 was essentially inactive. Morphine was less potent than MMG22 by >5-orders of magnitude and displayed tolerance. Subcutaneous MMG22 was effective (ED 50 = 2.41 mg/kg) and devoid of chronic tolerance. We propose that MMG22 induces the formation of a MOR-mGluR5 heteromer through selective interaction with the upregulated NR2B subunit of activated NMDAR, in view of the 4600-fold reduction of i.t. MMG22 antinociception by the selective NR2B antagonist, Ro25-6981. A possible explanation for the substantially reduced potency for MMG22 in the SNI model is discussed. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
8. Modulation of Cell Surface Expression of Nonactivated Cholecystokinin Receptors Using Bivalent Ligand-Induced Internalization.
- Author
-
Harikumar, Kaleeckal G., Akgün, Eyup, Portoghese, Philip S., and Miller, Laurence J.
- Abstract
CCK2 receptor antagonists potentiate pain relief by MOP receptor agonists. In an attempt to enhance this effect, we prepared bivalent ligands incorporating CCK2 receptor antagonist and MOP receptor agonist pharmacophores. Ligands with 16- to 22-atom spacers could simultaneously bind both receptors but provided no advantage in activity over individual ligands. We now examine the effect of these ligands on receptor internalization as a mechanism of receptor regulation. We prepared CHO cell lines expressing nonfluorescent halves (YN and YC) of yellow fluorescent protein attached to each receptor. Spatial approximation of constructs was needed to yield fluorescence. Monovalent MOP agonist 1 signaled normally and internalized the MOP receptor. Monovalent CCK2 antagonist 2 did not stimulate receptor internalization. In the dual receptor-bearing cells, bivalent ligands 3a−c capable of simultaneously binding both receptors resulted in cell surface fluorescence and internalization of the fluorescent complex in a time- and temperature-dependent manner. Bivalent ligand 4 with spacer too short to occupy both receptors simultaneously yielded no signal. Receptor tethering with appropriate bivalent ligands can down-regulate signaling by moving a nonactivated receptor into the endocytic pathway. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
9. Absence of conditioned place preference or reinstatement with bivalent ligands containing mu-opioid receptor agonist and delta-opioid receptor antagonist pharmacophores
- Author
-
Lenard, Natalie R., Daniels, David J., Portoghese, Philip S., and Roerig, Sandra C.
- Subjects
- *
OPIOID receptors , *MORPHINE , *PSYCHIATRIC drugs , *PAIN management - Abstract
Abstract: Treatment of pain with opioids is limited by their potential abuse liability. In an effort to develop analgesics without this side effect, a series of bivalent ligands containing a mu-opioid receptor agonist pharmacophore connected to a delta-opioid receptor antagonist pharmacophore through variable-length spacers (16–21 atoms) was synthesized. Members of this series [mu-opioid receptor (M)-delta-opioid receptor (D)-agonist (A)-antagonists (N): MDANs] are antinociceptive in the tail flick assay, but antinociceptive tolerance and physical dependence do not develop to ligands having spacers with 19–21 atoms. The current studies compared the rewarding properties of three bivalent ligands (MDAN-16, -19 and -21) and a mu-opioid receptor agonist (MA-19) to those of morphine in the conditioned place preference assay in mice after i.v. administration. Place preference developed to morphine and to MA-19, but not to the MDANs. The responses to MDAN-16 were highly variable, although place preference of borderline significance appeared to develop. Reinstatement was also evaluated after extinguishing morphine conditioned place preference; morphine and MA-19, but not the MDANs, reinstated morphine conditioned place preference. Taken together, these results suggest that the bivalents are less rewarding compared to morphine in opioid-naïve mice and do not induce reinstatement in previously morphine-preferring mice. The lack of a conditioned place preference response for MDAN-19 and -21, compared to the equivocal results with MDAN-16, suggests a minimum distance requirement between mu-opioid receptor and delta-opioid receptor recognition sites. This requirement may reflect the binding of MDAN-19 and -21 to mu-opioid receptor–delta-opioid receptor heterodimeric receptors that block reward but not antinociception. [Copyright &y& Elsevier]
- Published
- 2007
- Full Text
- View/download PDF
10. Effects of κ-opioid receptor ligands on intracranial self-stimulation in rats.
- Author
-
Todtenkopf, Mark S., Marcus, Jacqueline F., Portoghese, Philip S., and Carlezon, William A.
- Subjects
- *
BRAIN stimulation , *CYCLIC adenylic acid , *DYNORPHINS , *MENTAL depression , *ANTIDEPRESSANTS , *ANHEDONIA , *LABORATORY rats - Abstract
Rationale. Elevations in cAMP response element binding protein (CREB) function within the mesolimbic system of rats reduce cocaine reward in place conditioning studies and increase immobility in the forced swim test. Each of these behavioral adaptations can be interpreted as a depressive-like effect (i.e., anhedonia, despair) that may reflect reduced activity of brain reward systems. Furthermore, each effect appears due to increases in CREB-mediated expression of dynorphin, since each is attenuated by intracranial injections of the κ-opioid receptor antagonist norBNI. Objectives. Intracranial self-stimulation (ICSS) studies were conducted in rats to determine whether administration of a κ-agonist would have depressive-like effects on brain stimulation reward, and whether pretreatment with a κ-antagonist would attenuate any such effects. Conditions that have depressive effects in people (e.g., drug withdrawal) increase the threshold amounts of stimulation required to sustain ICSS in rats. Methods. Sprague-Dawley rats with lateral hypothalamic stimulating electrodes were tested in a “curve-shift” variant of the ICSS procedure after systemic administration of the κ-agonist U-69593 alone, the novel κ-antagonist 5′-acetamidinoethylnaltrindole (ANTI) alone, or co-administration of both drugs. Results. U-69593 dose dependently increased ICSS thresholds, suggesting that activation of κ-receptors reduced the rewarding impact of the brain stimulation. ANTI had no effects on its own, but it attenuated increases in ICSS thresholds caused by the agonist. Conclusions. These data provide further evidence that stimulation of brain κ-receptors may trigger certain depressive-like signs, and that κ antagonists may have efficacy as antidepressants without having reward-related actions of their own. [ABSTRACT FROM AUTHOR]
- Published
- 2004
- Full Text
- View/download PDF
11. The bivalent ligand, MMG22, reduces neuropathic pain after nerve injury without the side effects of traditional opioids.
- Author
-
Speltz, Rebecca, Lunzer, Mary M., Shueb, Sarah S., Akgün, Eyup, Reed, Rachelle, Kalyuzhny, Alex, Portoghese, Philip S., and Simone, Donald A.
- Subjects
- *
DRUG side effects , *SCIATIC nerve injuries , *DORSAL root ganglia , *OPIOID receptors , *NERVES , *WOUNDS & injuries , *THERAPEUTIC use of narcotics , *ANALGESICS , *NEURALGIA , *ANIMAL experimentation , *CELL receptors , *RESEARCH funding , *LIGANDS (Biochemistry) , *HYPERALGESIA , *MICE , *NEUROTRANSMITTER receptors - Abstract
Abstract: Functional interactions between the mu opioid receptor (MOR) and the metabotropic glutamate receptor 5 (mGluR5) in pain and analgesia have been well established. MMG22 is a bivalent ligand containing MOR agonist (oxymorphamine) and mGluR5 antagonist (MPEP) pharmacophores tethered by a 22-atom linker. MMG22 has been shown to produce potent analgesia in several models of chronic inflammatory and neuropathic pain (NP). This study assessed the efficacy of systemic administration of MMG22 at reducing pain behavior in the spared nerve injury (SNI) model of NP in mice, as well as its side-effect profile and abuse potential. MMG22 reduced mechanical hyperalgesia and spontaneous ongoing pain after SNI, with greater potency early (10 days) as compared to late (30 days) after injury. Systemic administration of MMG22 did not induce place preference in naive animals, suggesting absence of abuse liability when compared to traditional opioids. MMG22 also lacked the central locomotor, respiratory, and anxiolytic side effects of its monomeric pharmacophores. Evaluation of mRNA expression showed the transcripts for both receptors were colocalized in cells in the dorsal horn of the lumbar spinal cord and dorsal root ganglia. Thus, MMG22 reduces hyperalgesia after injury in the SNI model of NP without the typical centrally mediated side effects associated with traditional opioids. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
12. Stereochemistry and innate immune recognition: (+)-norbinaltorphimine targets myeloid differentiation protein 2 and inhibits toll-like receptor 4 signaling.
- Author
-
Xiaozheng Zhang, Yinghua Peng, Grace, Peter M., Metcalf, Matthew D., Kwilasz, Andrew J., Yibo Wang, Tianshu Zhang, Siru Wu, Selfridge, Brandon R., Portoghese, Philip S., Rice, Kenner C., Watkins, Linda R., Hutchinson, Mark R., and Xiaohui Wang
- Abstract
Deregulation of innate immune TLR4 signaling contributes to various diseases including neuropathic pain and drug addiction. Naltrexone is one of the rare TLR4 antagonists with good blood-brain barrier permeability and showing no stereoselectivity for TLR4. By linking 2 naltrexone units through a rigid pyrrole spacer, the bivalent ligand norbinaltorphimine was formed. Interestingly, (+)-norbinaltorphimine [(+)-1] showed ~25 times better TLR4 antagonist activity than naltrexone in microglial BV-2 cell line, whereas (-)-norbinaltorphimine [(-)-1] lost TLR4 activity. The enantioselectivity of norbinaltorphimine was further confirmed in primary microglia, astrocytes, and macrophages. The activities of meso isomer of norbinaltorphimine and the molecular dynamic simulation results demonstrate that the stereochemistry of (+)-1 is derived from the (+)-naltrexone pharmacophore. Moreover, (+)-1 significantly increased and prolonged morphine analgesia in vivo. The efficacy of (+)-1 is long lasting. This is the first report showing enantioselective modulation of the innate immune TLR signaling. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
13. Bivalent ligand MCC22 potently attenuates nociception in a murine model of sickle cell disease.
- Author
-
Cataldo, Giuseppe, Lunzer, Mary M., Olson, Julie K., Akgün, Eyup, Belcher, John D., Vercellotti, Gregory M., Portoghese, Philip S., and Simone, Donald A.
- Subjects
- *
SICKLE cell anemia , *NOCICEPTIVE pain , *LIGANDS (Biochemistry) , *LIPOPOLYSACCHARIDES , *HYPERALGESIA , *PAIN management , *THERAPEUTIC use of narcotics , *ANALGESICS , *ANIMAL experimentation , *BIOLOGICAL models , *MICE , *NARCOTICS , *SENSORY perception , *RESEARCH funding , *PHARMACODYNAMICS - Abstract
Sickle cell disease (SCD) is a chronic inflammatory disorder accompanied by chronic pain. In addition to ongoing pain and hyperalgesia, vaso-occlusive crises-induced pain can be chronic or episodic. Because analgesics typically used to treat pain are not very effective in SCD, opioids, including morphine, are a primary treatment for managing pain in SCD but are associated with many serious side effects, including constipation, tolerance, addiction, and respiratory depression. Thus, there is a need for the development of novel treatments for pain in SCD. In this study, we used the Townes transgenic mouse model of SCD to investigate the antinociceptive efficacy of the bivalent ligand, MCC22, and compared its effectiveness with morphine. MCC22 consists of a mu-opioid receptor agonist and a chemokine receptor-5 (CCR5) antagonist that are linked through a 22-atom spacer. Our results show that intraperitoneal administration of MCC22 produced exceptionally potent dose-dependent antihyperalgesia as compared to morphine, dramatically decreased evoked responses of nociceptive dorsal horn neurons, and decreased expression of proinflammatory cytokines in the spinal cord. Moreover, tolerance did not develop to its analgesic effects after repeated administration. In view of the extraordinary potency of MCC22 without tolerance, MCC22 and similar compounds may vastly improve the management of pain associated with SCD. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
14. Bivalent ligand that activates mu opioid receptor and antagonizes mGluR5 receptor reduces neuropathic pain in mice.
- Author
-
Peterson, Cristina D., Kitto, Kelley F., Akgün, Eyup, Lunzer, Mary M., Riedl, Maureen S., Vulchanova, Lucy, Wilcox, George L., Portoghese, Philip S., and Fairbanks, Carolyn A.
- Subjects
- *
CHRONIC pain , *CHRONIC diseases , *LIPOPOLYSACCHARIDES , *ENDOTOXINS , *DRUG synergism - Abstract
Themu opioid receptor (MOR) and metabotropic glutamate receptor = (mGluR5) are well-established pharmacological targets in the management of chronic pain. Both receptors are expressed in the spinal cord. MMG22, a bivalent ligand containing 2 pharmacophores separated by 22 atoms, which simultaneously activates MOR and antagonizes mGluR5, has been shown to produce potent reversal of tactile hypersensitivity in rodent models of lipopolysaccharide (LPS)-and bone cancer-induced chronic pain. This study assessed whether intrathecal MMG22 also is effective in reducing pain of neuropathic origin. Furthermore, we theorized that MMG22 should reduce hyperalgesia in nerve-injured mice in a manner consistent with a synergistic interaction between MOR and mGluR5. Several weeks after spared nerve injury, tactile hypersensitivity was reversed in mice by the intrathecal injection of MMG22 (0.01-10 nmol) but also by its shorter spacer analog, MMG10, with similar potency. The potencies of the bivalent ligands were 10- to 14-fold higher than those of the compounds upon which the bivalent structure was based, the MOR agonist oxymorphone and the mGluR5 antagonist MPEP. Coadministration of oxymorphone and MPEP demonstrated analgesic synergism, an interaction confirmed by isobolographic analysis. This study indicates that in the spared nerve injury-induced model of neuropathic pain, the 2 pharmacophores of the bivalent ligands MMG22 and MMG10 target MOR and mGluR5 as separate receptor monomers. The observed increase in the potency of MMG22 and MMG10, compared with oxymorphone and MPEP, may reflect the synergistic interaction of the 2 pharmacophores of the bivalent ligand acting at their respective separate receptor monomers. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
15. Modulation of musculoskeletal hyperalgesia by brown adipose tissue activity in mice.
- Author
-
Goudie-DeAngelis, Elizabeth M., Abdelhamid, Ramy E., Nunez, Myra G., Kissel, Casey L., Kovács, Katalin J., Portoghese, Philip S., and Larson, Alice A.
- Subjects
- *
ADIPOSE tissues , *MUSCULOSKELETAL system diseases , *LABORATORY mice , *FIBROMYALGIA , *BODY temperature regulation , *PATIENTS , *SWIMMING , *ADRENERGIC beta agonists , *ANIMAL experimentation , *BIOLOGICAL models , *BODY temperature , *BODY weight , *COLD (Temperature) , *ETHANOLAMINES , *HYPERALGESIA , *MICE , *MUSCLE strength , *REACTION time , *RESEARCH funding , *PAIN threshold , *PSYCHOLOGY - Abstract
Cold exposure and a variety of types of mild stress increase pain in patients with painful disorders such as fibromyalgia syndrome. Acutely, stress induces thermogenesis by increasing sympathetic activation of beta-3 (β3) adrenergic receptors in brown adipose tissue. Chronic stress leads to the hypertrophy of brown adipose, a phenomenon termed adaptive thermogenesis. Based on the innervation of skeletal muscle by collaterals of nerves projecting to brown adipose, we theorized an association between brown adipose tissue activity and musculoskeletal hyperalgesia and tested this hypothesis in mice. Exposure to a cold swim or injection of BRL37344 (β3 adrenergic agonist) each enhanced musculoskeletal hyperalgesia, as indicated by morphine-sensitive decreases in grip force responses, whereas SR59230A (β3 adrenergic antagonist) attenuated swim-induced hyperalgesia. Chemical ablation of interscapular brown adipose, using Rose Bengal, attenuated the development of hyperalgesia in response to either swim stress or BRL37344. In addition, elimination of the gene expressing uncoupling protein-1 (UCP1), the enzyme responsible for thermogenesis, prevented musculoskeletal hyperalgesia in response to either a swim or BRL37344, as documented in UCP1-knockout (UCP1-KO) mice compared with wild-type controls. Together, these data provide a convergence of evidence suggesting that activation of brown adipose contributes to stress-induced musculoskeletal hyperalgesia. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
16. Targeting putative mu opioid/metabotropic glutamate receptor-5 heteromers produces potent antinociception in a chronic murine bone cancer model.
- Author
-
Smeester, Branden A., Lunzer, Mary M., Akgün, Eyup, Beitz, Alvin J., and Portoghese, Philip S.
- Subjects
- *
OPIOIDS , *GLUTAMATE receptors , *ANALGESICS , *BONE cancer , *LABORATORY mice , *CHRONIC pain , *DISEASE progression , *CANCER pain - Abstract
The therapeutic management of chronic pain associated with many cancers is problematic due to the development of tolerance and other adverse effects during the disease progression. Recently we reported on a bivalent ligand (MMG22) containing both mu agonist and mGluR 5 antagonist pharmacophores that produced potent antinociception in mice with LPS-induced acute inflammatory pain via a putative MOR-mGluR 5 heteromer. In the present study we have investigated the antinociception of MMG22 in a mouse model of bone cancer pain to determine its effectiveness in reducing this type of chronic nociception. There was a 572-fold increase in the potency of MMG22 over a period of 3–21 days that correlated with the progressive increase in hyperalgesia induced by bone tumor growth following implantation of fibrosarcoma cells in mice. The enhancement of antinociception with the progression of the cancer is possibly due to inhibition of NMDA receptor-mediated hyperalgesia via antagonism of mGluR 5 and concomitant activation of MOR by the MMG22-occupied heteromer. Notably, MMG22 was 3.6-million-fold more potent than morphine at PID 21. Since MMG22 exhibited a 250,000-times greater potency than that of a mixture of the mu opioid (M19) agonist and mGluR 5 antagonist (MG20) monovalent ligands, the data suggest that targeting the putative MOR-mGluR 5 heteromer is far superior to univalent interaction with receptors in reducing tumor-induced nociception. In view of the high potency, long duration (>24 h) of action and minimal side effects, MMG22 has the potential to be a superior pharmacological agent than morphine and other opiates in the treatment of chronic cancer pain and to serve as a novel pharmacologic tool. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
17. Stereospecific synthesis of pseudocodeine: [2,3]-sigmatropic rearrangement using selenium...
- Author
-
Kshirsagar, Tushar A., Moe, Scott T., and Portoghese, Philip S.
- Subjects
- *
ORGANIC chemistry , *LIGANDS (Chemistry) - Abstract
Examines the chemical importance of the intermediate pseudocodeine in the synthesis of opiate ligands. Extensive use of the selenium and sulfur; Information on the allylic selenoxide; What the stereospecific synthesis involves.
- Published
- 1998
- Full Text
- View/download PDF
18. Putative Kappa Opioid HeteromersAs Targets for Developing Analgesics Free of Adverse Effects.
- Author
-
Le Naour, Morgan, Lunzer, Mary M., Powers, Michael D., Kalyuzhny, Alexander E., Benneyworth, Michael A., Thomas, Mark J., and Portoghese, Philip S.
- Subjects
- *
OPIOIDS , *ANALGESIC synthesis , *DRUG development , *G protein coupled receptors , *DRUG side effects , *ARRESTINS , *IMMUNOFLUORESCENCE - Abstract
It is now generally recognized thatupon activation by an agonist, β-arrestin associates with Gprotein-coupled receptors and acts as a scaffold in creating a diversesignaling network that could lead to adverse effects. As an approachto reducing side effects associated with κ opioid agonists,a series of β-naltrexamides 3–10was synthesized in an effort to selectively target putative κopioid heteromers without recruiting β-arrestin upon activation.The most potent derivative 3(INTA) strongly activatedKOR-DOR and KOR-MOR heteromers in HEK293 cells. In vivo studies revealed 3to produce potent antinociception, which, when taken togetherwith antagonism data, was consistent with the activation of both heteromers. 3was devoid of tolerance, dependence, and showed no aversiveeffect in the conditioned place preference assay. As immunofluorescencestudies indicated no recruitment of β-arrestin2 to membranesin coexpressed KOR-DOR cells, this study suggests that targeting ofspecific putative heteromers has the potential to identify leads foranalgesics devoid of adverse effects. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
19. BivalentLigands That Target μ Opioid (MOP)and Cannabinoid1 (CB1) Receptors Are Potent AnalgesicsDevoid of Tolerance.
- Author
-
Le Naour, Morgan, Akgün, Eyup, Yekkirala, Ajay, Lunzer, Mary M., Powers, Mike D., Kalyuzhny, Alexander E., and Portoghese, Philip S.
- Subjects
- *
LIGANDS (Biochemistry) , *OPIOID peptides , *CENTRAL nervous system , *CELL culture , *MOLECULAR interactions , *IMMUNOFLUORESCENCE - Abstract
Given that μ opioid (MOP) andcanabinoid (CB1)receptors are colocalized in various regions of the central nervoussystem and have been reported to associate as heteromer (MOP-CB1) in cultured cells, the possibility of functional, endogenousMOP-CB1in nociception and other pharmacologic effectshas been raised. As a first step in investigating this possibility,we have synthesized a series of bivalent ligands 1–5that contain both μ agonist and CB1antagonistpharmacophores for use as tools to study the functional interactionbetween MOP and CB1receptors in vivo. Immunofluorescentstudies on HEK293 cells coexpressing both receptors suggested 5(20-atom spacer) to be the only member of the series thatbridges the protomers of the heteromer. Antinociceptive testing inmice revealed 5to be the most potent member of the series.As neither a mixture of monovalent ligands 9+ 10nor bivalents 2–5producedtolerance in mice, MOR-CB1apparently is not an importanttarget for reducing tolerance. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
20. Ligands that interact with putative MOR-mGluR5 heteromer in mice with inflammatory pain produce potent antinociception.
- Author
-
Akgün, Eyup, Javed, Muhammad I., Lunzer, Mary M., Smeester, Branden A., Beitz, Al J., and Portoghese, Philip S.
- Subjects
- *
CHRONIC pain treatment , *LABORATORY mice , *MORPHINE , *OPIOID analgesics , *OPIOID receptors - Abstract
The low effectiveness of morphine and related mu opioid analgesics for the treatment of chronic inflammatory pain is a result of opioid-induced release of proinflammatory cytokines and glutamate that lower the pain threshold. In this regard, the use of opioids with metabotropic glutamate-5 receptor (mGluR5) antagonist has been reported to increase the efficacy of morphine and prevent the establishment of adverse effects during chronic use. Given the presence of opioid receptors (MORs) and mGluR5 in glia and neurons, together with reports that suggest coexpressed MOR/mGluR5 receptors in cultured cells associate as a heteromer, the possibility that such a heteromer could be a target in vivo was addressed by the design and synthesis of a series of bivalent ligands that contain mu opioid agonist and mGluR5 antagonist pharmacophores linked through spacers of varying length (10-24 atoms). The series was evaluated for antinociception using the tail-flick and von Frey assays in mice pretreated with lipopolysaccharide (LPS) or in mice with bone cancer. In LPS-pretreated mice, MMG22 (4c, 22-atom spacer) was the most potent member of the series (intrathecal ED50 ~9 fmol per mouse), whereas in untreated mice its ED50 was more than three orders of magnitude higher. As members of the series with shorter or longer spacers have ⩾500-fold higher ED50s in LPS-treated mice, the exceptional potency of MMG22 may be a result of the optimal bridging of protomers in a putative MOR-mGluR5 heteromer. The finding that MMG22 possesses a >106 therapeutic ratio suggests that it may be an excellent candidate for treatment of chronic, intractable pain via spinal administration. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
21. Reduced Antinociceptionof Opioids in Rats and Mice by Vaccination with Immunogens ContainingOxycodone and Hydrocodone Haptens.
- Author
-
Pravetoni, Marco, Le Naour, Morgan, Tucker, Ashli M., Harmon, Theresa M., Hawley, Tara M., Portoghese, Philip S., and Pentel, Paul R.
- Subjects
- *
OPIOIDS , *LABORATORY rats , *LABORATORY mice , *VACCINATION , *IMMUNOGENETICS , *OXYCODONE , *HAPTENS , *HEMOCYANIN - Abstract
Prescription opioids abuse and associated deaths arean emerging concern in the USA. Vaccination against prescription opioidsmay provide an alternative to pharmacotherapy. An oxycodone haptencontaining a tetraglycine linker at the C6 position (6OXY(Gly)4OH) conjugated to keyhole limpet hemocyanin (KLH) has shownearly proof-of-efficacy in rodents as a candidate immunogen (6OXY(Gly)4–KLH) for the treatment of oxycodone abuse. In thisstudy, oxycodone-based and hydrocodone-based haptens were conjugatedto KLH to generate immunogens that would recognize both oxycodoneand hydrocodone. Vaccination with 6OXY(Gly)4–KLHincreased drug binding in serum, reduced drug distribution to brain,and blunted analgesia for both oxycodone and hydrocodone. An analogousC6-linked hydrocodone vaccine blocked hydrocodone effects but lessso than 6OXY(Gly)4–KLH. C8-Linked hydrocodone immunogenshad only limited efficacy. Amide conjugation showed higher haptenationratios and greater efficacy than thioether conjugation to maleimideactivated KLH (mKLH). The 6OXY(Gly)4–KLH vaccinemay be used for treatment of prescription opioid abuse. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
22. Molecular Basis for Binding and Subtype Selectivity of 1,4-Benzodiazepine Antagonist Ligands of the Cholecystokinin Receptor.
- Author
-
Cawston, Erin E., Lam, Polo C. H., Harikumar, Kaleeckal G., Dong, Maoqing, Ball, Alicja M., Augustine, Mary Lou, Akgün, Eyup, Portoghese, Philip S., Orry, Andrew, Abagyan, Ruben, Sexton, Patrick M., and Miller, Laurence J.
- Subjects
- *
BENZODIAZEPINES , *CHOLECYSTOKININ receptors , *PEPTIDES , *STEREOCHEMISTRY , *G protein coupled receptors - Abstract
Allosteric binding pockets in peptide-binding G protein-coupled receptors create opportunities for the development of small molecule drugs with substantial benefits over orthosteric ligands. To gain insights into molecular determinants for this pocket within type 1 and 2 cholecystokinin receptors (CCK1R and CCK2R), we prepared a series of receptor constructs in which six distinct residues in TM2, -3, -6, and -7 were reversed. Two novel iodinated CCK1R- and CCK2R-selective 1,4-benzodiazepine antagonists, differing only in stereochemistry at C3, were used. When all six residues within CCK1R were mutated to corresponding CCK2R residues, benzodiazepine selectivity was reversed, yet peptide binding selectivity was unaffected. Detailed analysis, including observations of gain of function, demonstrated that residues 6.51, 6.52, and 7.39 were most important for binding the CCK1R-selective ligand, whereas residues 2.61 and 7.39 were most important for binding CCK2Rselective ligand, although the effect of substitution of residue 2.61 was likely indirect. Ligand-guided homology modeling was applied to wild type receptors and those reversing benzodiazepine binding selectivity. The models had high predictive power in enriching known receptor-selective ligands from related decoys, indicating a high degree of precision in pocket definition. The benzodiazepines docked in similar poses in both receptors, with C3 urea substituents pointing upward, whereas different stereochemistry at C3 directed the C5 phenyl rings and N1 methyl groups into opposite orientations. The geometry of the binding pockets and specific interactions predicted for ligand docking in these models provide a molecular framework for understanding ligand selectivity at these receptor subtypes. Furthermore, the strong predictive power of these models suggests their usefulness in the discovery of lead compounds and in drug development programs. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
23. Opioid Activity of SpinallySelective Analogues of N-Naphthoyl-β-naltrexaminein HEK-293 Cells and Mice.
- Author
-
Le Naour, Morgan, Lunzer, Mary M., Powers, Mike D., and Portoghese, Philip S.
- Subjects
- *
OPIOID receptors , *NALTREXONE , *LIGANDS (Biochemistry) , *LABORATORY mice , *GENE expression , *KIDNEYS , *ORGANIC synthesis - Abstract
Using the selective muâkappa agonist, N-naphthoyl-β-naltrexamine 1, as theprototypeligand, a series of closely related naphthalene analogues were synthesizedto study the chemical space around the naphthalene moiety in an effortto evaluate how receptor selectivity is affected by chemical modification.Nine analogues (2â10) of compound 1were synthesized and tested on HEK-293 cells expressing homomericand heteromeric opioid receptors, and in the mouse tail-flick assay.It was found that a small change in structure produces profound changesin selectivity in this series. This is exemplified by the discoverythat introduction of a 6-fluoro group transforms 1froma selective muâkappa heteromeric receptor agonist to a delta-preferringagonist 7. The in vivo studies reveal that many of theligands are more potent spinally than supraspinally and devoid oftolerance. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
24. MDAN-21: A Bivalent Opioid Ligand Containing mu-Agonist and Delta-Antagonist Pharmacophores and Its Effects in Rhesus Monkeys.
- Author
-
Aceto, Mario D., Harris, Louis S., Stevens Negus, S., Banks, Matthew L., Hughes, Larry D., Akgün, Eyup, and Portoghese, Philip S.
- Subjects
- *
OPIOID receptors , *LIGANDS (Biochemistry) , *RHESUS monkeys , *CHEMICAL inhibitors , *DRUG therapy , *MORPHINE , *ANALGESICS , *HEALTH outcome assessment , *ALLODYNIA , *THERAPEUTICS - Abstract
MDAN-21, 7'-{2-[(7-{2-[({(5α,6α)-4,5-Epoxy-3,14-dihydroxy-17-methylmorphin-6-yl}-aminocarbonyl)metoxy]-acetylamino} -heptylaminocarbonyl)-methoxy]-acetylamino}-naltrindole, a bivalent opioid ligand containing a mu-opioid receptor agonist (derived from oxymorphone) linked to the delta-opioid receptor antagonist (related to naltrindole) by a spacer of 21 atoms, was reported to have potent analgesic properties in mice. Tolerance, physical dependence, and conditioned place preference were not evident in that species. The finding that bivalent ligands in this series, with spacers 19 atoms or greater, were devoid of tolerance and dependence led to the proposal that MDAN-21 targets heteromeric mu-delta-opioid receptors. The present study focused on its effects in nonhuman primates (Macaca mulatta), a species with a physiology and behavioral repertoire not unlike humans. With regard to opioids, this species usually better predicts clinical outcomes. MDAN-21 substituted for morphine in morphinedependent monkeys in the remarkably low dose range 0.006-0.032 mg/kg, subcutaneously. Although MDAN-21 failed to produce reliable thermal analgesia in the dose range 0.0032-0.032 mg/kg, intramuscularly, it was active in the same dose range and by the same route of administration, in the capsaicin-induced thermal allodynia assay. The results suggest that MDAN-21 may be useful in the treatment of opioid dependence and allodynia. The data provide additional evidence that opioid withdrawal is associated with sensitized pain. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
25. N-naphthoyl-β-naltrexamine (NNTA), a highly selective and potent activator of μ/κ-opioid heteromers.
- Author
-
Yekkirala, Ajay S., Lunzer, Mary M., McCurdy, Christopher R., Powers, Michael D., Kalyuzhny, Alexander E., Roerig, Sandra C., and Portoghese, Philip S.
- Subjects
- *
G proteins , *CELL receptors , *FIRE assay , *PAIN management , *ANALGESICS - Abstract
Numerous G protein-coupled receptors (GPCRs) have been shown to form heteromeric receptors in cell-based assays. Among the many heteromers reported in the opioid receptor family are μ/κκ, κ/δ, and μ/δ. However, the in vivo physiological and behavioral relevance for the proposed heteromers have not yet been established. Here we report a unique example of a ligand, N-naphthoyl-β-naltrexamine (NNTA) that selectively activates heteromeric μ/κ-opioid receptors in HEK-293 cells and induces potent antinociception in mice. NNTA was an exceptionally potent agonist in cells expressing μ/κ-opioid receptors. Intriguingly, it was found to be a potent antagonist in cells expressing only μ-receptors. In the mouse tail-flick assay, intrathecal (i.t.) NNTA produced antinociception that was ~100-fold greater than by intracerebroventricular (i.c.v.) administration. The κ-antagonist, norBNI, decreased the i.t. potency, and the activity was virtually abolished in μ-opioid receptor knockout mice. No tolerance was induced i.t., but marginal tolerance (3-fold) was observed via the i.c.v. route. Moreover, NNTA produced neither significant physical dependence nor place preference in the ED50 dose range. Taken together, this work provides an important pharmacologic tool for investigating the in vivo functional relevance of heteromeric μ/κ-opioid receptors and suggests an approach to potent analgesics with fewer deleterious side effects. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
26. Naloxone acts as a potent analgesic in transgenic mouse models of sickle cell anemia.
- Author
-
Lunzer, Mary M., Yekkirala, Ajay, Hebbel, Robert P., and Portoghese, Philip S.
- Subjects
- *
NALOXONE , *MORPHINE , *ANALGESICS , *TRANSGENIC mice , *SICKLE cell anemia , *GENETIC disorders , *CHEMOKINES - Abstract
Sickle cell anemia is a common genetic disorder in African Americans. Opioid analgesics are traditionally the treatment for the severe pain associated with this disease. Here we reveal that the opioid antagonist naloxone possesses potent analgesic activity in two transgenic mouse models of sickle cell anemia (NY1DD and hBERK1) and not in their respective controls (ICR-CD1 and C57BL/6J) when administered by three parenteral routes [intracerebroventricular (i.c.v.), intrathecal, and subcutaneous]. In the NYIDD mice, naloxone (i.c.v.) possessed ≈300-fold greater potency than morphine (i.c.v.). Other opioid antagonists (naltrexone, norbinaltorphimine, and naltrindole) were substantially less effective in producing analgesia. Naloxone and morphine were synergistic in NY1DD mice, suggesting different receptor systems. Microarray analysis suggested naloxone-induced down-regulation of the CC chemokine receptor (CCR)5 in NY1DD mice but not in control mice. Pretreatment of control mice with CC chemokine ligand S [CCL5 (RANTES)] enabled naloxone to produce analgesia similar to that observed in NY1DD mice. Mu opioid receptor knockout mice treated similarly also displayed analgesia. That the effect of CCL5 was specifically related to CCR5 and/or CCR1 activation was demonstrated by antagonism of analgesia with the chemokine antagonist methionylated RANTES. Similar antagonism of naloxone-induced analgesia also was observed when NY1DD mice were pretreated with methionylated RANTES. These results indicate that CCR5/CCR1 receptors are directly or indirectly involved in analgesia produced by naloxone. The present study suggests that naloxone may be clinically useful in the treatment of pain associated with sickle cell disease and other disorders involving inflammation. [ABSTRACT FROM AUTHOR]
- Published
- 2007
- Full Text
- View/download PDF
27. Opiold-induced tolerance and dependence in mice is modulated by the distance between pharmacophores in a bivalent ligand series.
- Author
-
Daniels, David J., Lenard, Natalie R., Etienne, Chris L., Ping-Yee Law, Roerig, Sandra C., and Portoghese, Philip S.
- Subjects
- *
OPIOID receptors , *LIGANDS (Biochemistry) , *MORPHINE , *ANALGESICS , *OPIOIDS , *OPIOID abuse - Abstract
Given the mounting evidence for involvement of δ opioid receptors in the tolerance and physical dependence of μ opioid receptor agonists, we have investigated the possible physical interaction between μ and δ opioid receptors by using bivalent ligands. Based on reports of suppression of antinociceptive tolerance by the δ antagonist naltrindole (NTI), bivalent ligands [μ-δ-agonist-antagonist (MDAN) series] that contain different length spacers, and pharmacophores derived from NTI and the μ agonist oxymorphone, have been synthesized and evaluated by intracerebroven- tricular (i.c.v.) administration in the tail-flick test in mice. In acute i.c.v. studies, the bivalent ligands functioned as agonists with potencies ranging from 1.6- to 45-fold greater than morphine. In contrast, the monovalent μ agonist analogues were substantially more potent than the MDAN congeners and were essentially equipotent with one another and oxymorphone. Pretreatment with NTI decreased the ED50 values for MDAN-19 to a greater degree than for MDAN-16 but had no effect on MDAN-21. Chronic i.c.v. studies revealed that MDAN ligands whose spacer was 16 atoms or longer produced less dependence than either morphine or μ monovalent control MA-19. On the other hand, both physical dependence and tolerance were suppressed at MDAN spacer lengths of 19 atoms or greater. These data suggest that physical interaction between the μ and δ opioid receptors modulates μ-mediated tolerance and dependence. Because MDAN-21 was found to be 50-fold more potent than morphine by the i.v. route (i.v.), it offers a previously uncharacterized approach for the development of analgesics devoid of tolerance and dependence. [ABSTRACT FROM AUTHOR]
- Published
- 2005
- Full Text
- View/download PDF
28. Criteria for the safety evaluation of flavoring substances: The Expert Panel of the Flavor and Extract Manufacturers Association
- Author
-
Smith, Robert L., Cohen, Samuel M., Doull, John, Feron, Victor J., Goodman, Jay I., Marnett, Lawrence J., Munro, Ian C., Portoghese, Philip S., Waddell, William J., Wagner, Bernard M., and Adams, Timothy B.
- Subjects
- *
FLAVOR , *FOOD chemistry , *FLAVOR research , *TOXICITY testing , *ASSOCIATIONS, institutions, etc. - Abstract
Abstract: The current status of the GRAS evaluation program of flavoring substances operated by the Expert Panel of FEMA is discussed. The Panel maintains a rigorous rotating 10-year program of continuous review of scientific data related to the safety evaluation of flavoring substances. The Panel concluded a comprehensive review of the GRAS (GRASa) status of flavors in 1985 and began a second comprehensive review of the same substances and any recently GRAS materials in 1994. This second re-evaluation program of chemical groups of flavor ingredients, recognized as the GRAS reaffirmation (GRASr) program, is scheduled to be completed in 2005. The evaluation criteria used by the Panel during the GRASr program reflects the significant impact of advances in biochemistry, molecular biology and toxicology that have allowed for a more complete understanding of the molecular events associated with toxicity. The interpretation of novel data on the relationship of dose to metabolic fate, formation of protein and DNA adducts, enzyme induction, and the cascade of cellular events leading to toxicity provides a more comprehensive basis upon which to evaluate the safety of the intake of flavor ingredients under conditions of intended use. The interpretation of genotoxicity data is evaluated in the context of other data such as in vivo animal metabolism and lifetime animal feeding studies that are more closely related to actual human experience. Data are not viewed in isolation, but comprise one component that is factored into the Panel’s overall safety assessment. The convergence of different methodologies that assess intake of flavoring substances provides a greater degree of confidence in the estimated intake of flavor ingredients. When these intakes are compared to dose levels that in some cases result in related chemical and biological effects and the subsequent toxicity, it is clear that exposure to these substances through flavor use presents no significant human health risk. [Copyright &y& Elsevier]
- Published
- 2005
- Full Text
- View/download PDF
29. A heterodimer-selective agonist shows in vivo relevance of G protein-coupled receptor dimers.
- Author
-
Waldhoer, Maria, Fong, Jamie, Jones, Robert M., Lunzer, Mary M., Sharma, Shiv K., Kostenis, Evi, Portoghese, Philip S., and Whistler, Jennifer L.
- Subjects
- *
G proteins , *MEMBRANE proteins , *DRUG interactions , *IATROGENIC diseases , *ANESTHESIA , *CENTRAL nervous system - Abstract
There has been much speculation regarding the functional relevance of G protein-coupled receptor heterodimers, primarily because demonstrating their existence in vivo has proven to be a considerable challenge. Here we show that the opioid agonist ligand 6'-guanidinonaltrindole (6'-GNTI) has the unique property of selectively activating only opioid receptor heterodimers but not homomers. Importantly, 6'-GNTI is an analgesic, thereby demonstrating that opioid receptor heterodimers are indeed functionally relevant in vivo. However, 6'-GNTI induces analgesia only when it is administered in the spinal cord but not in the brain, suggesting that the organization of heterodimers is tissue-specific. This study demonstrates a proof of concept for tissue-selective drug targeting based on G protein-coupled receptor heterodimerization. Importantly, targeting opioid heterodimers could provide an approach toward the design of analgesic drugs with reduced side effects. [ABSTRACT FROM AUTHOR]
- Published
- 2005
- Full Text
- View/download PDF
30. Specific Cross-Linking of Lys233 and Cys235 in the Mu Opioid Receptor by a Reporter Affinity Label.
- Author
-
Zhang, Yan, Mccurdy, Christopher R., Metzger, Thomas G., and Portoghese, Philip S.
- Subjects
- *
LYSINE , *AMINO acids , *ISOINDOLE , *CYSTOMETRY , *BLADDER examination , *NAPHTHALENE , *POLYCYCLIC aromatic hydrocarbons - Abstract
The first example of the use of a reporter affinity label (NNA) that contains a fluorogenic naphthalene dialed moiety to identify neighboring lysine and cysteine residues at a recognition site is described. The opted receptors have served as the proof-of-concept because they contain multiple lysine and cysteine residues. The kinetics of isoindole formation resulting from covalent binding of NNA to wild-type and mutant opted receptors were followed in cultured cells using flow cystometry. The finding that NNA bound to mutant mu opted receptors (K233R and C235S) without producing specific fluorescence enhancement suggested that covalent bonding occurred at these positions to produce an isoindole fluorophore in the wild-type mu receptor. The similar kinetics of fluorophore formation for wild-type mu, delta, and kappa opted receptors suggest that these conserved residues are the cross-linking sites in all three types of opted receptors. The combined utilization of a reporter affinity label and site-directed mutagenesis offers a more expeditious method of identifying cross-linking at a recognition site when compared to classical procedures. [ABSTRACT FROM AUTHOR]
- Published
- 2005
- Full Text
- View/download PDF
31. The FEMA GRAS assessment of cinnamyl derivatives used as flavor ingredients
- Author
-
Adams, Timothy B., Cohen, Samuel M., Doull, John, Feron, Victor J., Goodman, Jay I., Marnett, Lawrence J., Munro, Ian C., Portoghese, Philip S., Smith, Robert L., Waddell, William J., and Wagner, Bernard M.
- Subjects
- *
SAFETY , *FLAVORING essences , *FLAVORING essences industry , *EXTRACTS , *CHEMICAL kinetics - Abstract
This publication is the seventh in a series of safety evaluations performed by the Expert Panel of the Flavor and Extract Manufacturers Association (FEMA). In 1993, the Panel initiated a comprehensive program to re-evaluate the safety of more than 1700 GRAS flavoring substances under conditions of intended use. Elements that are fundamental to the safety evaluation of flavor ingredients include exposure, structural analogy, metabolism, pharmacokinetics and toxicology. Flavor ingredients are evaluated individually and in the context of the available scientific information on the group of structurally related substances. Scientific data relevant to the safety evaluation of the use of cinnamyl derivatives as flavoring ingredients is evaluated. [Copyright &y& Elsevier]
- Published
- 2004
- Full Text
- View/download PDF
32. Kappa opioid antagonist effects of the novel kappa antagonist 5′-guanidinonaltrindole (GNTI) in an assay of schedule-controlled behavior in rhesus monkeys.
- Author
-
Negus, Stevens S., Mello, Nancy K., Linsenmayer, David C., Jones, M., and Portoghese, Philip S.
- Subjects
- *
OPIOID receptors , *CHEMICAL inhibitors - Abstract
Rationale: Opioid receptors are divided into three types: kappa, mu, and delta receptors. Receptor-selective antagonists are useful experimental tools for evaluation of opioid receptor-mediated processes. 5'-Guanidinonaltrindole (GNTI) was recently developed as a novel kappa-selective antagonist. Objectives: To evaluate the potency, time course, and selectivity of GNTI's opioid antagonist effects in rhesus monkeys in an assay of schedule-controlled responding. Methods: Five rhesus monkeys were trained to respond under a fixed ratio 30 schedule of food reinforcement. The rate-decreasing effects of the kappa agonists U50,488 and U69,593, the mu agonist morphine, and the delta agonist SNC80 were examined alone and after pretreatment with GNTI (0.1 and 1.0 mg/kg i.m.; 1 h to 14 days). Results: U50,488, U69,593, morphine, and SNC80 dose-dependently decreased response rates in this procedure. GNTI produced a dose- and time-dependent antagonism of the rate-decreasing effects of U50,488. The kappa antagonist effects of GNTI had a slow onset and a long duration of action, and peak antagonist effects were observed after 24 h. A higher dose of 3.2 mg/kg GNTI eliminated responding in one monkey and was not studied further. The antagonist effects of GNTI were kappa selective, because 1.0 mg/kg GNTI also antagonized the effects of U69,593, but not those of morphine or SNC80. Conclusions: These results suggest that GNTI is a potent and selective kappa antagonist with a slow onset and long duration of action in rhesus monkeys. Relative to the prototype kappa antagonist nor-binaltorphimine, GNTI may have some advantages as a tool for the study of kappa receptor-mediated processes. [ABSTRACT FROM AUTHOR]
- Published
- 2002
- Full Text
- View/download PDF
33. The δ[sub 2] -opioid receptor antagonist naltriben reduces motivated responding for ethanol.
- Author
-
June, Harry L., McCane, Shannan R., Zink, Richard W., Portoghese, Philip S., Li, Ting-Kai, and Froehlich, Janice C.
- Subjects
- *
ALCOHOLIC beverages , *ALCOHOL , *PEOPLE with alcoholism , *LABORATORY rats - Abstract
Abstract Rationale: Given that alcoholics drink for different reasons, it is not likely that a single pharmacotherapeutic agent will be equally effective for all alcoholics. Hence, the development of new pharmacotherapeutic agents that are capable of reducing alcohol intake remains an important focus in the field of alcohol research. Objective: The objective of the present study was to examine the effects of the delta[sub 2] receptor antagonist naltriben (0.60-4.0 mg/kg) on operant responding maintained by the presentation of ethanol (EtOH) or saccharin in alcohol-preferring (P) rats. Methods: P rats were trained under a concurrent schedule [fixed ratio (FR)4-FR4] to press one lever for EtOH (10% v/v) and another for saccharin (0.0125-0.05% w/v) during a 60-min session. Naloxone, a non-specific opioid receptor antagonist, served as a reference antagonist. Results: When responding maintained by EtOH and saccharin were equated under baseline conditions, naloxone (0.003125-0.75 mg/kg) reduced levels of EtOH-maintained responding by 46-82%. None of the naloxone doses significantly reduced responding maintained by saccharin. Naltriben (0.9-4.0 mg/kg) reduced EtOH-maintained responding by 44-76%, while saccharin-maintained responding was reduced only by the highest dose of naltriben (4.0 mg/kg). Analysis of the EtOH within-session response pattern revealed that naloxone suppressed EtOH-maintained responding during the entire operant session and led to early termination of responding. Low doses of naltriben (0.90 mg/kg and 1.2 mg/kg) suppressed responding during the latter portion of the operant session, while higher doses (2.0, 3.0, 4.0 mg/kg) decreased responding during the entire session and led to early termination of responding. Conclusions: The results of... [ABSTRACT FROM AUTHOR]
- Published
- 1999
- Full Text
- View/download PDF
34. A bivalent ligand (KMN-21) antagonist for μ/κ heterodimeric opioid receptors
- Author
-
Zhang, Shijun, Yekkirala, Ajay, Tang, Ye, and Portoghese, Philip S.
- Subjects
- *
OPIOID receptors , *DIMERS , *LIGANDS (Biochemistry) , *DRUG development , *PHARMACEUTICAL chemistry , *DRUG design - Abstract
Abstract: In an effort to develop antagonists for κ–μ opioid receptor heterodimers, a series of bivalent ligands 3–6 containing κ- and μ-antagonist pharmacophores were designed and synthesized. Evaluation of the series in HEK-293 cells revealed 4 (KMN-21) to selectively antagonize the activation of κ–μ heterodimers, suggesting possible bridging of receptors when the bivalent ligand spacer contains 21 atoms. [Copyright &y& Elsevier]
- Published
- 2009
- Full Text
- View/download PDF
35. Targeting MOR-mGluR5 heteromers reduces bone cancer pain by activating MOR and inhibiting mGluR5.
- Author
-
Shueb, Sarah S., Erb, Samuel J., Lunzer, Mary M., Speltz, Rebecca, Harding-Rose, Catherine, Akgün, Eyup, Simone, Donald A., and Portoghese, Philip S.
- Subjects
- *
CANCER pain , *BONE cancer , *PAIN management , *DRUG side effects , *BIOCHEMICAL mechanism of action , *HYPERALGESIA - Abstract
Pain is among the most common symptoms in cancer and approximately 90% of patients experience end-stage cancer pain. The management of cancer pain is challenging due to the significant side effects associated with opioids, and novel therapeutic approaches are needed. MMG22 is a bivalent ligand containing MOR agonist and mGluR 5 antagonist pharmacophores joined by a 22-atom spacer. MMG22 exhibited extraordinary analgesia following intrathecal administration in a mouse model of bone cancer pain. Here, we assessed the effectiveness of systemic administration of MMG22 in reducing cancer pain and evaluated whether MMG22 displays side effects associated with opioids. Fibrosarcoma cells were injected into and around the calcaneus bone in C3H mice. Mechanical hyperalgesia was defined as an increase in the paw withdrawal frequencies (PWFs) evoked by application of a von Frey monofilament (3.9 mN bending force) applied to the plantar surface of the hind paw Subcutaneous (s.c.), intramuscular (i.m.), and oral (p.o.) administration of MMG22 produced robust dose-dependent antihyperalgesia, whose ED 50 was orders of magnitude lower than morphine. Moreover, the ED 50 for MMG22 decreased with disease progression. Importantly, s.c. administration of MMG22 did not produce acute (24 h) or long-term (9 days) tolerance, was not rewarding (conditioned place preference test), and did not produce naloxone-induced precipitated withdrawal or alter motor function. A possible mechanism of action of MMG22 is discussed in terms of inhibition of spinal NMDAR via antagonism of its co-receptor, mGluR 5 , and concomitant activation of neuronal MOR. We suggest that MMG22 may be a powerful alternative to traditional opioids for managing cancer pain. This article is part of the Special Issue entitled 'New Vistas in Opioid Pharmacology'. • Systemic administration OF MMG22 targets a MOR-mGluR5 heteromer and potently reduces bone cancer pain in mice. • MMG22 does not possess adverse effects associated with traditional opioids. • MMG22 activates MOR and antagonizes mGluR5. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
36. The bivalent ligand MCC22 potently attenuates hyperalgesia in a mouse model of cisplatin-evoked neuropathic pain without tolerance or reward.
- Author
-
Cataldo, Giuseppe, Erb, Samuel J., Lunzer, Mary M., Luong, Nhungoc, Akgün, Eyup, Portoghese, Philip S., Olson, Julie K., and Simone, Donald A.
- Subjects
- *
OPIOID receptors , *PAIN tolerance , *PERIPHERAL neuropathy , *ANTINEOPLASTIC agents , *CHEMOKINE receptors , *HYPERALGESIA , *REINFORCEMENT learning - Abstract
Cisplatin and other widely employed platinum-based anticancer agents produce chemotherapy-induced peripheral neuropathy (CIPN) that often results in pain and hyperalgesia that are difficult to manage. We investigated the efficacy of a novel bivalent ligand, MCC22, for the treatment of pain arising from CIPN. MCC22 consists of mu opioid receptor (MOR) agonist and chemokine receptor 5 (CCR5) antagonist pharmacophores connected through a 22-atom spacer and was designed to target a putative MOR-CCR5 heteromer localized in pain processing areas. Mice received once daily intraperitoneal (i.p.) injections of cisplatin (1 mg/kg) for seven days and behavior testing began 7 days later. Cisplatin produced mechanical hyperalgesia that was decreased dose-dependently by MCC22 given by intrathecal (ED 50 = 0.004 pmol) or i.p. (3.07 mg/kg) routes. The decrease in hyperalgesia was associated with decreased inflammatory response by microglia in the spinal cord. Unlike morphine, MCC22 given daily for nine days did not exhibit tolerance to its analgesic effect and its characteristic antihyperalgesic activity was fully retained in morphine-tolerant mice. Furthermore, MCC22 did not alter motor function and did not exhibit rewarding properties. Given the exceptional potency of MCC22 without tolerance or reward, MCC22 has the potential to vastly improve management of chronic pain due to CIPN. This article is part of the Special Issue entitled 'New Vistas in Opioid Pharmacology'. • Chemotherapy often causes peripheral neuropathy that can be chronic and painful. • The bivalent ligand, MCC22, consists of a mµ opioid receptor agonist and a CCR5 receptor antagonist. • MCC22 potently reduced chemotherapy-induced hyperalgesia produced by cisplatin in mice. • MCC22 did not produce tolerance or reward. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
37. Bivalent ligand that activates mu opioid receptor and antagonizes mGluR5 receptor reduces neuropathic pain in mice.
- Author
-
Peterson, Cristina D, Kitto, Kelley F, Akgün, Eyup, Lunzer, Mary M, Riedl, Maureen S, Vulchanova, Lucy, Wilcox, George L, Portoghese, Philip S, and Fairbanks, Carolyn A
- Subjects
- *
ANALGESICS , *ANIMALS , *CELL receptors , *HYPERALGESIA , *SPINAL injections , *LIGANDS (Biochemistry) , *MICE , *NARCOTIC antagonists , *NEURALGIA , *NEUROTRANSMITTER receptors , *PHARMACODYNAMICS - Abstract
The mu opioid receptor (MOR) and metabotropic glutamate receptor 5 (mGluR5) are well-established pharmacological targets in the management of chronic pain. Both receptors are expressed in the spinal cord. MMG22, a bivalent ligand containing 2 pharmacophores separated by 22 atoms, which simultaneously activates MOR and antagonizes mGluR5, has been shown to produce potent reversal of tactile hypersensitivity in rodent models of lipopolysaccharide (LPS)-and bone cancer-induced chronic pain. This study assessed whether intrathecal MMG22 also is effective in reducing pain of neuropathic origin. Furthermore, we theorized that MMG22 should reduce hyperalgesia in nerve-injured mice in a manner consistent with a synergistic interaction between MOR and mGluR5. Several weeks after spared nerve injury, tactile hypersensitivity was reversed in mice by the intrathecal injection of MMG22 (0.01-10 nmol) but also by its shorter spacer analog, MMG10, with similar potency. The potencies of the bivalent ligands were 10- to 14-fold higher than those of the compounds upon which the bivalent structure was based, the MOR agonist oxymorphone and the mGluR5 antagonist MPEP. Coadministration of oxymorphone and MPEP demonstrated analgesic synergism, an interaction confirmed by isobolographic analysis. This study indicates that in the spared nerve injury-induced model of neuropathic pain, the 2 pharmacophores of the bivalent ligands MMG22 and MMG10 target MOR and mGluR5 as separate receptor monomers. The observed increase in the potency of MMG22 and MMG10, compared with oxymorphone and MPEP, may reflect the synergistic interaction of the 2 pharmacophores of the bivalent ligand acting at their respective separate receptor monomers. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.